ACM
MRSN

Altium Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Altium Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-42,365
Closed -$1.35M – 82
2023
Q3 		$1.35M Buy
+42,365
New +$2.01M 0.7% 32

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Altium Capital Management's MRSN Position: Q4 2023 in Review

Altium Capital Management sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 42,365 shares — an estimated $1.35M sold.

Altium Capital Management first reported a position in MRSN in Q3 2023 and held it in 1 quarter. The position peaked at $1.35M in Q3 2023. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Altium Capital Management reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Altium Capital Management sold 42,365 Mersana Therapeutics shares in Q4 2023, an estimated $1.35M.
  • Altium Capital Management first reported a position in Mersana Therapeutics in Q3 2023 and held it in 1 quarter.
  • Altium Capital Management's Mersana Therapeutics position peaked at $1.35M in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Altium Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.